NYSE:NUVB - Nuvation Bio Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $17.40
Forecasted Upside: 97.06 %
Number of Analysts: 6
Breakdown:
0 Sell Ratings
0 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$8.83 As of 07/26/2021 04:59 PM ET

▲ +0.22 (2.56%)

1 month | 3 months | 12 months

Get New Nuvation Bio Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for NUVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVB

^$17.40

▲ +97.06% Upside Potential

This price target is based on 6 analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $17.40, with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 97.06% upside from the last price of $8.83.

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Nuvation Bio.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/6/2021	Royal Bank of Canada	Initiated Coverage	Outperform	$15.00	High
3/15/2021	BTIG Research	Reiterated Rating	Buy	$16.00	High
3/8/2021	Jefferies Financial Group	Initiated Coverage	Buy	$20.00	High
3/8/2021	Cowen	Initiated Coverage	Outperform		High
3/8/2021	Wedbush	Initiated Coverage	Outperform	$20.00	High
3/8/2021	BTIG Research	Initiated Coverage	Buy	$16.00	High
3/8/2021	BMO Capital Markets	Initiated Coverage	Outperform	$16.00	High

(Data available from 7/26/2016 forward)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.

Today's Range

Now: $8.83

$8.39

$8.97

50 Day Range

MA: $9.87

$8.25

$13.53

52 Week Range

Now: $8.83

$8.15

$15.23

Volume

16,536 shs

Average Volume

781,241 shs

Market Capitalization

$1.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuvation Bio?

The following Wall Street research analysts have issued stock ratings on Nuvation Bio in the last twelve months: BMO Capital Markets, BTIG Research, Cowen Inc, Jefferies Financial Group Inc., Royal Bank of Canada, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for NUVB.

What is the current price target for Nuvation Bio?

5 Wall Street analysts have set twelve-month price targets for Nuvation Bio in the last year. Their average twelve-month price target is $17.40, suggesting a possible upside of 104.7%. Jefferies Financial Group Inc. has the highest price target set, predicting NUVB will reach $20.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $15.00 for Nuvation Bio in the next year.
View the latest price targets for NUVB.

What is the current consensus analyst rating for Nuvation Bio?

Nuvation Bio currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NUVB will outperform the market and that investors should add to their positions of Nuvation Bio.
View the latest ratings for NUVB.

What other companies compete with Nuvation Bio?

Other companies that are similar to Nuvation Bio include Arrowhead Pharmaceuticals, Evotec, HUTCHMED, Ascendis Pharma A/S, Perrigo, Legend Biotech, Ultragenyx Pharmaceutical, Apellis Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, TG Therapeutics, Cassava Sciences, I-Mab, Blueprint Medicines and Schrödinger.

How do I contact Nuvation Bio's investor relations team?

Nuvation Bio's physical mailing address is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. The company's listed phone number is 650-245-3818 and its investor relations email address is [email protected] The official website for Nuvation Bio is www.nuvationbio.com.